Miyuki Matsukawa
Overview
Explore the profile of Miyuki Matsukawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murota H, Nakahara T, Noto S, Matsukawa M, Takeda H, Toda R
Dermatol Ther (Heidelb)
. 2025 Jan;
15(2):291-305.
PMID: 39812943
Introduction: The impact of atopic dermatitis (AD) on daily life and different levels of quality of life (QOL) according to AD severity has not been fully elucidated. This study aimed...
2.
Higashihara E, Matsukawa M, Jiang H
Clin Exp Nephrol
. 2025 Jan;
PMID: 39747793
Background: Despite of long-lasting tolvaptan treatment, individual renal outcomes are unclear in autosomal dominant polycystic kidney disease (ADPKD). This post-hoc analysis of the TEMPO 3:4 trial aimed to evaluate the...
3.
Nakahara T, Noto S, Matsukawa M, Takeda H, Zhang Y, Kondo T
Dermatol Ther (Heidelb)
. 2024 Nov;
14(11):3113-3132.
PMID: 39487325
Introduction: Difamilast has proven to be an effective treatment for the treatment of atopic dermatitis (AD) in Japan, but its cost-effectiveness remains unknown. Therefore, the objective of the current study...
4.
Nakahara T, Murota H, Matsukawa M, Takeda H, Zhang Y, Kondo T
Dermatol Ther (Heidelb)
. 2024 Oct;
14(10):2905-2916.
PMID: 39367273
Background: Atopic dermatitis (AD) is a chronic condition with an increasing incidence in Japan. Difamilast and delgocitinib are both new topical drugs for AD proven to be efficacious and safe...
5.
Shiraishi Y, Kurita Y, Mori H, Ooishi K, Matsukawa M
ESC Heart Fail
. 2024 Aug;
11(6):4061-4070.
PMID: 39105376
Aims: To help establish optimized treatment strategies for congestion in patients with acute heart failure, this study aimed to provide a detailed summary of real-world diuretic use in hospitalized patients...
6.
Ishii R, Sakai F, Sano H, Nakai M, Koga N, Matsukawa M
Front Neurol
. 2024 Jul;
15:1440733.
PMID: 39045427
Objective: This study aimed to describe the migraine burden and healthcare utilization in the context of headache frequency using nationwide claims data linked to online survey data previously collected in...
7.
Mochizuki T, Matsukawa M, Tanaka T, Jiang H
Kidney360
. 2024 Feb;
5(4):522-528.
PMID: 38414126
No abstract available.
8.
Shibata T, Matsumoto S, Muramoto T, Matsukawa M
J Cardiol
. 2024 Feb;
84(1):47-54.
PMID: 38311113
Background: There is a concern that the coronavirus disease 2019 (COVID-19) pandemic has led to underutilization of non-invasive positive pressure ventilation (NPPV) in patients with acute heart failure (HF). We...
9.
Shiraishi Y, Kurita Y, Mori H, Oishi K, Matsukawa M
Circ J
. 2023 Dec;
88(5):680-691.
PMID: 38143082
Background: This retrospective observational study investigated the incidence of worsening renal function (WRF) in patients hospitalized for heart failure (HF) and treated with intravenous diuretics in Japan. Methods and results:...
10.
Hagiwara D, Matsukawa M, Tasaki J, Nakamura Y, Arima H
Endocr J
. 2023 Nov;
70(12):1195-1205.
PMID: 37914256
We aimed to survey the status of tolvaptan administration in routine clinical practice since the approval of a novel indication for treating syndrome of inappropriate secretion of antidiuretic hormone (SIADH)...